1. Home
  2. IBRX vs LCII Comparison

IBRX vs LCII Comparison

Compare IBRX & LCII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • LCII
  • Stock Information
  • Founded
  • IBRX 2014
  • LCII 1956
  • Country
  • IBRX United States
  • LCII United States
  • Employees
  • IBRX N/A
  • LCII N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • LCII Auto Parts:O.E.M.
  • Sector
  • IBRX Health Care
  • LCII Consumer Discretionary
  • Exchange
  • IBRX Nasdaq
  • LCII Nasdaq
  • Market Cap
  • IBRX 2.3B
  • LCII 2.2B
  • IPO Year
  • IBRX N/A
  • LCII N/A
  • Fundamental
  • Price
  • IBRX $2.81
  • LCII $100.29
  • Analyst Decision
  • IBRX Strong Buy
  • LCII Buy
  • Analyst Count
  • IBRX 5
  • LCII 4
  • Target Price
  • IBRX $11.40
  • LCII $104.33
  • AVG Volume (30 Days)
  • IBRX 7.3M
  • LCII 385.8K
  • Earning Date
  • IBRX 08-11-2025
  • LCII 08-05-2025
  • Dividend Yield
  • IBRX N/A
  • LCII 4.55%
  • EPS Growth
  • IBRX N/A
  • LCII 66.37
  • EPS
  • IBRX N/A
  • LCII 6.10
  • Revenue
  • IBRX $31,222,000.00
  • LCII $3,818,769,000.00
  • Revenue This Year
  • IBRX $567.98
  • LCII $7.21
  • Revenue Next Year
  • IBRX $160.56
  • LCII $5.06
  • P/E Ratio
  • IBRX N/A
  • LCII $16.43
  • Revenue Growth
  • IBRX 10238.41
  • LCII 1.04
  • 52 Week Low
  • IBRX $1.83
  • LCII $72.31
  • 52 Week High
  • IBRX $7.48
  • LCII $129.38
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 51.33
  • LCII 66.38
  • Support Level
  • IBRX $2.68
  • LCII $95.47
  • Resistance Level
  • IBRX $3.00
  • LCII $102.72
  • Average True Range (ATR)
  • IBRX 0.16
  • LCII 2.99
  • MACD
  • IBRX -0.00
  • LCII 0.76
  • Stochastic Oscillator
  • IBRX 62.00
  • LCII 83.77

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About LCII LCI Industries

LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.

Share on Social Networks: